Two pancreatic-enzyme products approved

Two pancreatic-Enzyme products approved

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Ultresa (pancrelipase) was approved for adults and children with and other disorders that affect food digestion because the pancreas does not produce enough enzymes, the FDA said.

The second drug, Viokace (pancrelipase), is to be used in combination with a to treat adults with pancreatitis. This drug's safety and effectiveness have not been established in children, the agency said.

About 200,000 people in the United States have "pancreatic insufficiency" disorders, according to the FDA. The two new medications are the fourth and fifth to be approved for these conditions.

Both new drugs are produced by Aptalis Pharma US, based in Bridgewater, N.J.

More information: Medline Plus has more about pancreatic diseases.

add to favorites email to friend print save as pdf

Related Stories

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

Recommended for you

Boxed warnings are common in novel therapeutics

12 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

13 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

14 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments